TORONTO – Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has  announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2. This follows Moderna’s submission to the U.S. Food and Drug Administration for …